Frequently Asked Questions

Beacon is a decision-grade drug development intelligence platform trusted by 24/25 top pharmaceutical companies. Purpose-built for complex modalities and diseases, Beacon combines scientifically verified preclinical, clinical, commercial and patent data into one structured intelligence layer.

Teams use Beacon to benchmark competitors, evaluate targets and indications, identify partnering opportunities, optimize clinical and portfolio strategy, monitor emerging trends, and power AI and data science workflows with trusted intelligence. By replacing fragmented research with connected, traceable evidence, Beacon helps teams reach faster and more defensible R&D decisions.

Generalist databases are designed for breadth across industries, which can leave gaps in the scientific depth needed for complex drug development. Beacon uses specialist modality- and disease-specific datasets, proprietary ontologies and expert scientific curation to capture the variables that determine meaningful differentiation.

Generic databases and AI tools can miss an estimated 20–30% of complex-modality landscapes, including early-stage assets and critical preclinical evidence. Beacon gives teams a fuller, more granular and traceable view, reducing the time spent cleaning, validating and reconciling third-party data.

Trusted by 24 of the top 25 pharmaceutical companies, Beacon is used across preclinical research, clinical development, pipeline and portfolio strategy, competitive intelligence (CI), business development (BD), search and evaluation, and data science teams.

• Researchers use Beacon to benchmark targets, modalities, constructs, delivery approaches and experimental strategies against the full preclinical landscape, helping them identify differentiation opportunities and make more informed research decisions.
• Clinical development teams use Beacon to compare trial designs, endpoints, biomarkers, patient populations and outcomes to optimise development strategies and benchmark competitive progress.
• Strategy, CI and BD teams use the same structured data to assess landscapes, competitors, assets, partners and whitespace.
• Data science and IT teams can integrate Beacon into internal dashboards, models and AI workflows, creating a consistent evidence base across the organisation.

Beacon is designed to complement existing data platforms rather than simply duplicate them. It adds specialist modality- and disease-specific depth, particularly across preclinical design, clinical development and complex scientific attributes that broader sources may not capture consistently. Because assets, targets, indications, trials, mechanisms and outcomes are linked, teams can reduce manual cross-referencing and validation.

Beacon data can also feed dashboards, models and AI workflows through integration capabilities, helping organisations turn existing technology investments into more reliable decision-support systems.

Beacon is best suited to biopharma and biotech organizations, life science investors and service providers, and specialist teams making high-value scientific, clinical, portfolio, partnering and competitive decisions. It is particularly valuable in complex landscapes where broad financial or pipeline databases lack the depth needed for meaningful benchmarking.

• Biopharma teams can apply Beacon’s decision-grade intelligence to R&D, portfolio and partnering decisions.
• Investors can connect scientific, clinical, company and deal intelligence to screen opportunities, validate differentiation, assess technical risk and build investment conviction using traceable evidence.

Specialist modules cover individual modalities and disease areas, allowing organisations to select the intelligence most relevant to their priorities or combine modules for a broader cross-modality and cross-disease view.

Beacon provides a comprehensive, decision-grade view of complex drug development landscapes, combining scientifically verified preclinical, clinical, company and commercial intelligence in a single platform. With complete, structured and traceable data, teams can identify competitive risks, emerging programmes, scientific design patterns and potential whitespace more quickly and confidently.

This accelerates landscape assessment, benchmarking, portfolio reviews and search-and-evaluation activities while reducing the manual effort required to find, clean, classify and validate fragmented data. Because every record is scientifically reviewed and traceable to primary sources, insights can be used with confidence in strategic discussions and high-stakes decisions.

Beacon helps preclinical research teams benchmark targets, modalities, constructs and development strategies against the full competitive landscape. Researchers can compare target selection, construct design, delivery approaches, preclinical models, efficacy, safety and other modality-specific variables across relevant programmes to identify differentiation opportunities and avoid repeating known challenges.

By bringing fragmented scientific evidence into a single structured view, Beacon accelerates landscape assessment, hypothesis generation and experimental decision-making. Researchers can also connect preclinical findings with later clinical outcomes to better understand the design choices associated with success, failure, toxicity and durability.

Beacon helps clinical development teams benchmark trial strategies within the scientific and competitive context of their landscape. Users can compare patient populations, biomarkers, endpoints, combinations, study design, results, safety signals and competitor progress.

The connected data makes it easier to understand how development choices differ across similar programmes and where the landscape is moving. These insights can strengthen protocol planning, indication strategy, competitive assessment and interpretation of new readouts.

Beacon gives business development and search-and-evaluation teams a connected view of targets, indications, assets, companies, deals and development maturity. Users can identify potential partners and opportunities while assessing the scientific evidence and competitive context behind each programme.

Granular modality- and disease-specific data helps teams compare assets on true points of differentiation rather than relying on high-level pipeline descriptions. This supports faster screening, more focused diligence and more defensible prioritisation of opportunities.

Beacon consolidates pipeline movements, trial progress, company activity, funding and deals within a structured intelligence environment. Competitive intelligence teams can monitor established competitors while also identifying early-stage programmes that may be missed by broader tools. Modality-specific filters make it possible to segment landscapes by the scientific and clinical variables that matter most. This enables repeatable, evidence-backed analysis of strategic shifts, emerging threats and future competitive scenarios.

Beacon enables teams to map whitespace across assets, targets, technologies, modalities and indications, revealing where markets are crowded and where scientifically or commercially attractive opportunities may remain. This helps teams focus investment and development on areas with stronger potential for differentiation, while identifying unmet need and avoiding increasingly congested parts of the landscape.

Beyond whitespace mapping, Beacon helps teams answer the strategic questions that shape R&D, competitive intelligence, portfolio strategy and business development. Users can benchmark targets, constructs, delivery approaches and development strategies to understand which design choices are associated with success, failure or toxicity; compare internal assets with competing programmes; and assess how trial strategies, clinical progress and emerging data are changing the competitive landscape.

Teams can also use Beacon to identify emerging competitors and potential threats, evaluate targets and indications, screen potential assets and partners, assess differentiation, and prioritise opportunities for further diligence. By connecting granular preclinical, clinical, company and commercial intelligence, Beacon helps teams move beyond simply asking who is developing what to addressing the more important strategic questions: Where should we play? How can we differentiate? Which opportunities have the strongest potential? And what could change our competitive position?

Beacon connects internal portfolio questions with competetive drug development intelligence across assets, targets, indications, trials, mechanisms and outcomes. Teams can benchmark programmes against relevant competitors and evaluate whether differentiation is supported by scientific and clinical evidence. The platform helps reveal crowded areas, emerging whitespace, changing standards and risks that may affect future value. This supports more informed investment, prioritization and go/no-go decisions, backed by data that can be traced to primary sources.

Beacon links drugs, trials, targets, indications, modalities, mechanisms, outcomes, commercial profiles, deals and patents within a single structured intelligence layer. For each asset, teams can connect its design characteristics with preclinical evidence, clinical strategy, trial results, competitive context and related company activity. The relationships between datasets support analysis across the full development pathway rather than treating each record in isolation. This connected structure is designed for both human analysis and machine-driven workflows, including AI tools.

Beacon captures the granular variables that determine meaningful differentiation within each modality and disease area. Examples include ADC payload, linker, conjugation and DAR; cell source, delivery and costimulatory domain; and RNA delivery system, editing technology and tissue targeting. At disease and trial level, users can assess subtype, biomarker status, endpoints, combinations, results and safety. This depth enables like-for-like scientific and clinical benchmarking that is not possible from high-level pipeline entries alone.

Beacon reduces noise by structuring data around proprietary, modality-specific ontologies rather than broad generic classifications. Users can apply precision filters to isolate the technologies, mechanisms, targets, patient groups or development strategies relevant to their use case or research question. This makes it easier to analyse a tightly defined niche without manually reviewing large volumes of irrelevant results. The result is a clearer landscape and a faster path from search to actionable insight.

Beacon combines technology-enabled data capture with expert scientific review. Relevant data is captured from sources including journals, trial registries, patents, regulatory filings, press releases, conference abstracts and financial filings. Sector-specialist scientists then verify, classify, structure and quality-control each data point using modality- and disease-specific ontologies. Records are traceable to primary sources, giving teams evidence they can review and defend in scientific and strategic decision-making.

Beacon continuously scans public sources for new drug development intelligence. Relevant updates are reviewed, structured and integrated into the platform within 24–48 hours of publication. This gives users a current, up-to-date, view of pipeline changes, trial developments, company activity and emerging scientific evidence. Scientific verification remains part of the process, balancing speed with the accuracy and consistency required for high-value decisions.

Beacon is purpose-built for drug development intelligence within its covered complex modalities and disease areas. It is not intended to be a universal database for every therapeutic market, industry or data type. Coverage is defined by the scope and ontology of each specialist module, helping keep the data relevant and scientifically consistent. The Beacon support team can confirm whether a particular modality, disease, market or use case falls within the available coverage.

Beacon includes historical drug development evidence so users can examine how assets, trials, technologies and competitive landscapes have evolved over time. Please email support@beaconintel.com with any questions.

Beacon and generative AI are designed to work in tandem rather than compete. Generative AI offers a fast, natural-language way to ask questions and synthesise information, while Beacon provides the curated, structured and traceable evidence behind the answer.

Through the Beacon Model Context Protocol (MCP), approved AI assistants and internal workflows can connect securely to Beacon data instead of relying only on the open web. This improves the completeness, consistency and defensibility of AI-supported analysis, resulting in gold-standard data in, gold-standard decisions out.

Generative AI can produce fluent answers, but reliable analysis depends on the quality and structure of the underlying evidence. Beacon consistently links assets, companies, targets, indications, modalities, trials, mechanisms and outcomes, making them searchable and comparable across a landscape. This structured foundation supports repeatable analysis and allows conclusions to be traced back to primary sources. It also reduces the gaps, inconsistent classification and unverifiable outputs that can arise when AI works from fragmented web information alone.

Yes. Beacon supports saved searches and monitoring any change across relevant drugs, companies, indications and competitive landscapes. Users can focus on the areas that matter to them and surface new activity without repeatedly rebuilding the same analysis.

Beacon data can be exported to Excel for additional analysis, reporting and modelling, while individual records can be saved as PDFs for easy sharing and reference.

For more scalable integration, Beacon APIs enable data to be incorporated into internal dashboards, CRMs, data platforms and established workflows, including environments such as Snowflake, Databricks and Power BI.

Beacon’s Model Context Protocol (MCP) also enables approved AI assistants to connect securely to Beacon data for natural-language questions and analysis.

Together, these options help organisations integrate Beacon intelligence into the tools and workflows they already use..

Beacon provides expert-curated reports covering important developments, trends and emerging themes across modality and disease landscapes. Reports include digests that explore topics of interest, infographics, pre- and post-conference reports, conference presentations, and thought leadership articles, with new content released monthly.

Yes. Beacon supports teams before and after major industry conferences, helping them focus on the developments most relevant to their areas of interest. Pre-conference reports identify relevant talks and abstracts, organised by the scientific and clinical areas covered by Beacon, helping teams prioritise what to follow and make more efficient use of their time at the event.

Post-conference reports then provide expert analysis of the data presented, highlighting important developments across targets, assets, indications and emerging approaches, alongside structured summaries of relevant clinical and preclinical abstracts. This helps teams quickly understand what has changed, assess the implications for their competitive landscape and identify developments that warrant further investigation.

Yes. Beacon provides structured, evidence-backed data that teams can use to build internal presentations, portfolio reviews and strategic reports. Data can be analysed and visualised to map competitive landscapes, benchmark internal assets against competitors, identify whitespace, track pipeline and market changes, compare targets and technologies, assess development strategies, and support portfolio prioritisation or partnering decisions. This enables teams to turn complex drug development data into clear charts, comparisons and landscape views that can be shared with scientific, commercial and senior leadership stakeholders.

For teams requiring additional support, Beacon’s Customer Success and Consulting teams can help with further analysis. Beacon Consulting can provide deeper bespoke analysis and strategic deliverables, including landscape assessments, competitor benchmarking, whitespace analysis, opportunity sizing, data visualisations and executive-ready slide decks.

Beacon onboarding is designed to help teams become productive as quickly as possible. Our Customer Success team tailors onboarding to each team’s priority use cases, therapeutic landscapes, and workflows, ensuring users focus on the areas most relevant to their work from day one. Guided training shows users how to navigate Beacon, apply specialist filters, and build searches that answer real business and scientific questions. By focusing on live requirements rather than generic training, teams can move rapidly from platform orientation to generating meaningful insights. Ongoing support and best-practice guidance then help users refine and scale repeatable workflows as their needs evolve.

Beacon subscriptions include customer success support, platform guidance and training resources. The support is designed to help users apply Beacon to real scientific, competitive and strategic questions rather than simply learn individual features. Teams can refine searches, improve workflows and make better use of the available data as priorities change. This helps organisations embed Beacon into day-to-day analysis and gain sustained value from their subscription.

Yes. Beacon’s specialist and consulting teams can support bespoke questions and deeper strategic work when a standard platform search is not enough. Analysts can bring modality- and disease-specific context to complex landscape reviews, emerging areas and time-critical decisions. This complements internal analysis with expert interpretation grounded in Beacon’s structured data. The appropriate level of support can be discussed based on the scope and requirements of the project.

Beacon is provided through a subscription model based on the specialist data coverage and access an organisation requires. Customers can subscribe to individual modality or disease datasets aligned with their immediate priorities. Dastasets can also be combined, including cross-modality subscriptions, to create a broader view across technologies and therapeutic landscapes. Pricing is therefore shaped by the agreed module dataset coverage, number and type of users, and required level of access or support.

Beacon licences are assigned to named users to maintain secure, compliant and personalised access. Named access supports individual workflows, saved activity and appropriate account management. Shared logins are not supported because they reduce security and make access harder to manage responsibly. Where broader adoption is needed, Beacon can scope a suitable team or enterprise access model within the subscription.

Evaluation is typically delivered through a live demonstration tailored to your organisation’s real use cases, priority landscapes and data requirements. The Beacon team can use relevant examples to show the available coverage, granularity, search capabilities and connections between datasets. This allows stakeholders to assess how the platform would support their scientific, competitive or strategic workflows. The discussion also helps identify the most appropriate datasets and subscription structure before purchase.

Teams usually build the business case around reduced research and validation time, stronger benchmarking and better-informed decisions.

Beacon can replace fragmented manual work with a structured, repeatable view of the evidence, freeing specialists to spend more time interpreting insights.

The case is strongest when linked to priority workflows such as portfolio reviews, competitive monitoring, search and evaluation, trial benchmarking or AI enablement.

Organisations can also consider the risk and cost of acting on an incomplete, misclassified or unverifiable landscape.

Yes. Beacon supports enterprise single sign-on and access controls for secure deployment across organisations. SSO enables centralised access management and a streamlined sign-in experience aligned with internal IT policies. Named-user access helps ensure that only authorised users can reach the platform and associated workflows. These capabilities support wider organisational adoption while maintaining appropriate control over access.

Beacon handles website, platform and demonstration data in line with its applicable privacy and security requirements. Demonstrations can be tailored to a prospect’s use cases and data requirements without requiring confidential customer information to be entered into the platform.

Beacon’s underlying intelligence is sourced from public drug development materials and then structured and scientifically reviewed. Organisations with specific privacy, security or procurement requirements can discuss those requirements with the Beacon team as part of the evaluation process.